{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:29:06Z","timestamp":1794547746398,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GE2519\/8-2, GE2519\/9-2"],"award-info":[{"award-number":["GE2519\/8-2, GE2519\/9-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DU548\/9-1 (515982377)"],"award-info":[{"award-number":["DU548\/9-1 (515982377)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2051 \u2013 Project-ID 390713860"],"award-info":[{"award-number":["EXC 2051 \u2013 Project-ID 390713860"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GM1908E"],"award-info":[{"award-number":["01GM1908E"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Schilling Foundation"},{"name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung (IZKF) Jena"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic immune-mediated peripheral nerve myelinopathies (CIPNM) are progressive and debilitating disorders that can be refractory to current treatment regimes. The bispecific T-cell engager (BiTE) teclistamab depletes B-cell Maturation Antigen (BCMA) positive late-stage B- cells and plasma cells by engaging T-cells. We present two patients with treatment-refractory CIPNM (Patient 1: IgM-kappa-associated CIPNM, follow-up 9 months; Patient 2: Anti-myelin-associated-glycoprotein (MAG) antibody-mediated CIPNM, follow-up 6 months). Both patients are characterized by rapid improvement upon treatment with teclistamab: substantially increased walking distance, accompanied by reduced nerve swelling and markedly improved electroneurography. Furthermore, some nerves without stimulus response at baseline are showing detectable response during follow-up. The functional recovery of peripheral nerves is paralleled by decreased serum neurofilament levels, indicating reduced neuronal damage. IgM kappa paraprotein and high-titer MAG antibodies are undetectable 6 weeks after the first dose of teclistamab and remain negative throughout the follow-up, whereas soluble BCMA re-emerges following an initial reduction. No serious adverse events are observed during treatment. This case series highlights the significant therapeutic potential of teclistamab in treatment-refractory CIPNM and provides an important example of \u2018off-the-shelf\u2019 BiTE therapy being well tolerated and effective and should be further investigated in neuro-immunological disorders.<\/jats:p>","DOI":"10.1038\/s41467-026-73819-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:43:42Z","timestamp":1780116222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-3759","authenticated-orcid":false,"given":"Jonathan","family":"Wickel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Ceanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8830-0173","authenticated-orcid":false,"given":"Benjamin","family":"Vlad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-5809","authenticated-orcid":false,"given":"Nikolai","family":"von Stackelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nounagnon Romaric","family":"Tochoedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaposi","family":"Yomade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-134X","authenticated-orcid":false,"given":"Diana","family":"Dudziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-581X","authenticated-orcid":false,"given":"Christian","family":"Geis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"73819_CR1","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia, A. et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104\u20131105 (2023).","journal-title":"Lancet Neurol."},{"key":"73819_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","volume":"23","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A., Schett, G. & Mougiakakos, D. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Lancet Neurol. 23, 615\u2013624 (2024).","journal-title":"Lancet Neurol."},{"key":"73819_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","volume":"82","author":"FS Ismail","year":"2025","unstructured":"Ismail, F. S. et al. Current and future roles of chimeric antigen receptor T-cell therapy in neurology: a review. JAMA Neurol. 82, 93\u2013103 (2025).","journal-title":"JAMA Neurol."},{"key":"73819_CR4","doi-asserted-by":"crossref","unstructured":"Wickel, J. et al. Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep. Med.. 5, 101794 (2024).","DOI":"10.1016\/j.xcrm.2024.101794"},{"key":"73819_CR5","doi-asserted-by":"publisher","unstructured":"Crayle J., Pestronk A. Chronic immune peripheral nerve myelinopathies: a plea for precision. JAMA Neurol. (2025). https:\/\/doi.org\/10.1001\/jamaneurol.2025.2709","DOI":"10.1001\/jamaneurol.2025.2709"},{"key":"73819_CR6","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander, A. L. et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst. Rev. 1, CD010369 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"73819_CR7","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","volume":"80","author":"JM Leger","year":"2013","unstructured":"Leger, J. M. et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 80, 2217\u20132225 (2013).","journal-title":"Neurology."},{"key":"73819_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/jnnp-2024-334678","volume":"96","author":"YG Min","year":"2025","unstructured":"Min, Y. G., Visentin, A., Briani, C. & Rajabally, Y. A. Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management. J. Neurol. Neurosurg. Psychiatry 96, 340\u2013349 (2025).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"73819_CR9","doi-asserted-by":"publisher","unstructured":"Hanggi, P., Aliu, B., Martin, K., Herrendorff, R., Steck, A. J. Decrease in serum anti-MAG autoantibodies is associated with therapy response in patients with anti-MAG neuropathy: retrospective study. Neurol. Neuroimmunol. Neuroinflamm. 9 https:\/\/doi.org\/10.1212\/NXI.0000000000001109 (2022).","DOI":"10.1212\/NXI.0000000000001109"},{"key":"73819_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"73819_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen, M. et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N. Engl. J. Med. 391, 867\u2013869 (2024).","journal-title":"N. Engl. J. Med."},{"key":"73819_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander, T., Kronke, J., Cheng, Q., Keller, U. & Kronke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864\u2013866 (2024).","journal-title":"N. Engl. J. Med."},{"key":"73819_CR13","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMc2506740","volume":"393","author":"L Bucci","year":"2025","unstructured":"Bucci, L. et al. BCMA T-cell engager therapy in patients with refractory autoimmune disease. N. Engl. J. Med. 393, 1544\u20131547 (2025).","journal-title":"N. Engl. J. Med."},{"key":"73819_CR14","doi-asserted-by":"publisher","unstructured":"Schreiber S., et al. Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4(+) myasthenia gravis. Mol. Ther. (2025). https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.029","DOI":"10.1016\/j.ymthe.2025.06.029"},{"key":"73819_CR15","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci, L. et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat. Med. 30, 1593\u20131601 (2024).","journal-title":"Nat. Med."},{"key":"73819_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"73819_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 34, 985\u20131005 (2020).","journal-title":"Leukemia."},{"key":"73819_CR18","doi-asserted-by":"publisher","first-page":"577725","DOI":"10.1016\/j.jneuroim.2021.577725","volume":"361","author":"AJ Steck","year":"2021","unstructured":"Steck, A. J. Anti-MAG neuropathy: from biology to clinical management. J. Neuroimmunol. 361, 577725 (2021).","journal-title":"J. Neuroimmunol."},{"key":"73819_CR19","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1007\/s10072-021-05583-7","volume":"42","author":"H Koike","year":"2021","unstructured":"Koike, H. & Katsuno, M. Paraproteinemia and neuropathy. Neurol. Sci. 42, 4489\u20134501 (2021).","journal-title":"Neurol. Sci."},{"key":"73819_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","volume":"23","author":"JA Allen","year":"2024","unstructured":"Allen, J. A. et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 23, 1013\u20131024 (2024).","journal-title":"Lancet Neurol."},{"key":"73819_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/brain\/awae400","volume":"148","author":"E Nobile-Orazio","year":"2025","unstructured":"Nobile-Orazio, E. et al. Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial. Brain. 148, 1112\u20131121 (2025).","journal-title":"Brain."},{"key":"73819_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/jnnp-2023-333112","volume":"95","author":"L Querol","year":"2024","unstructured":"Querol, L. et al. Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study. J. Neurol. Neurosurg. Psychiatry. 95, 845\u2013854 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"73819_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awab422","volume":"145","author":"DR Cornblath","year":"2022","unstructured":"Cornblath, D. R. et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 145, 887\u2013896 (2022).","journal-title":"Brain."},{"key":"73819_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik, I. N. et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 17, 35\u201346 (2018).","journal-title":"Lancet Neurol."},{"key":"73819_CR25","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1016\/j.ymthe.2025.06.042","volume":"33","author":"T Ruck","year":"2025","unstructured":"Ruck, T. et al. CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes. Mol. Ther. 33, 4135\u20134142 (2025).","journal-title":"Mol. Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73819-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:16:45Z","timestamp":1780118205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73819-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73819"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73819-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: J.W. reports honoraria from Argenx, Alexion, travel support from Neuraxpharm, and research support from Ionis Pharmaceuticals. M.C. reports honoraria from Argenx. C.G. received speaker fees and compensation for advisory boards from Alexion, Roche, Sobi, Argenx, Kyowa, Astra Zeneca and travel support from Alexion. D.D. received compensation for advisory board from Johnson & Johnson and received funding from the company Affimed in an independent project. B.V., N.S., D.S., N.R.T., R.T., and O.Y. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4816"}}